Tempus AI partners with NYU Langone Health and Northwestern Medicine to broaden access to genomic testing, enhancing ...

Congresswoman Nancy Pelosi (D-Calif.) beat the stock market in 2025 with her investment portfolio posting gains once again.

U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower ...

Tempus AI stock contract value exceeds $1.1B with 70 pharma deals. Diagnostics revenue up 111%, data segment up 31% in 2025 ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Tempus AI specializes in developing artificial intelligence solutions to improve patient outcomes in various healthcare fields. Ark Invest reduced the Tempus AI position in the ARK Innovation ETF.

Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...

AI-powered data company Tempus AI announced it will acquire Paige, an AI-enabled diagnostic platform for oncologists and pathologists, for $81.25 million. Tempus said the acquisition will help the ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial-intelligence-powered programs for spotting the signs of cancer. The deal totals $81.25 million, ...

CANADA - 2025/04/23: In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) AstraZeneca ...

Tempus AI is appealing after a 10% pullback, seeing it as an opportunity following strong Q1 results and a short report-driven dip. The precision medicine company should top Q2 estimates, especially ...